No recent analyst price targets found for CURX.
Latest News for CURX
What's Behind Curanex Pharmaceuticals (CURX) 56% Surge After Hours
Curanex Pharmaceuticals shares surged in after-hours trading after the company completed a GMP-compliant batch supporting its planned IND submission for ulcerative colitis.
Curanex Provides Operational Update on Key Regulatory Milestones
Company Completes GMP Pilot for Phyto-N, Targets Ulcerative Colitis IND Submission Q4 2026 Jericho, New York, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the completion of a Good Manufacturing…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CURX.
U.S. House Trading
No House trades found for CURX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.